Although the usefulness of the MGMT promoter methylation analysis in patients with glioblastoma for predicting the response to chemoradiotherapy with temozolomide and the prognosis has been widely reported, no consensus has been reached regarding the number of CpG sites that should be tested in MGMT promoter methylation. This evidence concerns the gene MGMT and glioblastoma.